Metabolic and Neurofunctional Responses to Breakfasts

NCT02897570 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-09-14

No results posted yet for this study

Summary

This study aims at assessing the effects of glucose and different types of breakfast on metabolic and neurofunctional responses in healthy individuals.

Twelve healthy subjects, on a stable diet, in a randomized-crossover fashion, received either a 50 g glucose load (control) or one of these breakfast:

B1: milk (125ml) and cereals (30g); B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g); B3: milk (125ml), bread (50g), apple (150g) and hazelnut cream chocolate (15g). Prior and upon completion of each tolerance test, an EEG was performed to measure frontal P300-evoked potentials.

Conditions

  • Feeding Behaviors
  • Lack of Satiety
  • Attention Deficit and Disruptive Behavior Disorders

Interventions

DIETARY_SUPPLEMENT

Glucose

50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.

DIETARY_SUPPLEMENT

Milk & Cereals

A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed

DIETARY_SUPPLEMENT

Milk, apple & snack

A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.

DIETARY_SUPPLEMENT

Milk, apple & bread w/ cream

A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.

DEVICE

EEG_pre

Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials

DEVICE

EEG_post

Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials

Sponsors & Collaborators

  • Soremartec Italia S.r.l.

    collaborator UNKNOWN
  • Ospedale San Donato

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897570 on ClinicalTrials.gov